EU: Coronavirus -Remdesivir: Commission signs a joint procurement contract with Gilead for the supply of Remdesivir

 The Commission has signed a joint procurement framework contract with the pharmaceutical company Gilead for the supply of up to 500,000 treatment courses of Veklury, the brand name for Remdesivir, and the opportunity to increase supply beyond the 500,000 treatment courses. There are  36 signatories of the Joint Procurement Agreement participating in this joint procurement, including all EU countries, the EEA countries of Norway and Iceland*, the UK, as well as six candidate countries and potential candidates (Albania, the Republic of North Macedonia, Montenegro, Serbia, Kosovo** and Bosnia and Herzegovina). All participating countries can now place their orders to procure Veklury directly. Veklury is at this stage the only medicine with a conditional marketing authorisation in the EU for the treatment of COVID-19 patients needing oxygen supply.

Read more at: Coronavirus: Remdesivir

Remdesivir drug: Still many unanswered questions about remdesivir's potential as a COVID-19 treatment

The preliminary highlights from a major U.S. study suggesting an experimental drug can speed up the recovery of COVID-19 patients is exciting news that needs to be tempered with a healthy dose of caution until full details are released in a published study, say Canadian infectious disease experts.

Read more at:
https://www.cbc.ca/news/canada/edmonton/remdesivir-coronavirus-canadian-researchers-await-data-1.5552254